Four Decades of Impact: Pinang Medical Supplies and the Evolution of Homecare
It was a great privilege to meet with Mr. Teh, the founder of Pinang Medical Supplies Sdn Bhd (PMS), on 6 August 2026 at Global Rep. PMS established in 1980 and headquartered in Penang, Malaysia, is a leading distributor and retailer of medical devices, disposables, and healthcare products. With over four decades of experience, PMS has built a strong presence across Malaysia and Singapore, operating branches in Kuala Lumpur, Melaka, Johor, Ipoh, and its retail arm, HomeCare Shop, which is recognized as Malaysia’s largest home care chain store. The company supplies a wide range of products including wheelchairs, orthopedic supports, posture care devices, pain management tools, elderly care solutions, incontinence products, and daily living aids, while also distributing exclusive international brands such as Obena, OppO, Backjoy, Karma, Etac etc. PMS imports from multiple countries and procures locally, serving hospitals, clinics, pharmacies, and direct consumers, and has expanded into e-commerce through its own online store and platforms like Shopee. Renowned as a trusted market leader, PMS is committed to improving quality of life by making healthcare and wellness solutions accessible, affordable, and reliable. We conducted a comprehensive review of current trends, challenges, and the future outlook in homecare product supply, homecare services, nursing homes, and hospitals. The session with Mr. Teh was truly eye‑opening, and we were deeply impressed by his foresight regarding the homecare industry. We are honored to have gained insights into his vision for advancing homecare across multiple dimensions to benefit the community, as well as his strategy to support and nurture younger generations in building sustainable homecare businesses.We are pleased to extend to PMS our medical device registration services, enabling Global Rep to add value to a homecare industry that is rapidly evolving into a technology-driven, patient-centred ecosystem, fuelled by strong growth in Malaysia and globally due to aging populations, demand for aging-in-place solutions, and the integration of AI, remote monitoring, and personalized care. According to Coherent Market Insights, the global homecare market in 2026 is valued at over USD 650 billion, with medical equipment and elderly care driving the largest shares. North America leads with approximately 35% of the market, while Asia Pacific—including Malaysia—is rapidly expanding with a 25% share, fuelled by aging populations and the growing demand for aging-in-place solutions. The homecare business is both lucrative and future-proof, particularly in Malaysia where demographic trends and regulatory clarity create strong opportunities. Success in this sector depends on embracing technology adoption, delivering community-focused services, and maintaining strict compliance — especially in medical device registration and post-market surveillance. Most homecare products fall within the definition of medical devices. For example, wheelchairs provide mobility for individuals with disabilities or medical conditions; limb supports stabilize, align, or support weakened or injured body parts, serving a therapeutic role in rehabilitation, pain reduction, and mobility improvement; and posture care products help prevent, correct, or support musculoskeletal alignment. In line with the Malaysia Medical Device Act 2012, any establishment intending to market medical devices must ensure that the devices are duly registered prior to commercialization. Looking for a Reliable Local Authorized Representative or a Regulatory Affairs Support for Medical Devices? At Global Rep, we specialize in medical device regulatory affairs, empowering businesses by managing the full spectrum of regulatory requirements — from medical device registration and pre-market obligations to post-market changes and surveillance. As your trusted local authorized representative for medical device and regulatory affairs support, we allow our partners to stay compliant while focusing on what they do best: innovating, growing, and delivering value to the communities they serve.
Malaysia: Your Gateway to ASEAN Healthcare Growth
Leveraging Malaysia as a Strategic Investment Platform for Regional Expansion, Innovation and Healthcare Excellence Global Rep was honored to participate in the webinar organized by Informa Markets on 5 Aug 2026, where government representatives and industry leaders shared valuable insights on how Malaysia’s robust infrastructure, highly skilled workforce, and strong regional connectivity are enabling businesses to expand their presence and unlock new opportunities across one of the world’s fastest-growing healthcare markets. Malaysia stands out as a prime destination for healthcare investment in ASEAN. With a robust healthcare market, strong infrastructure, and political stability, it offers both affordability and innovation. Its medical tourism sector continues to expand, supported by advanced facilities and the Malaysia Healthcare Travel Council (MHTC). Strategic initiatives like the World Health Expo Kuala Lumpur further connect investors to regional opportunities, making Malaysia a thriving hub for healthcare growth and partnerships. Overview The webinar discussed Malaysia’s strategic role in ASEAN healthcare growth. Mr. Abdul Halim Muhammad Shariff (Abdul Halim), Deputy Director of the Life Science and Lifestyle Section at the Malaysia External Trade Development Corporation (MATRADE), highlighted Malaysia’s healthcare ecosystem, including its $21.6 billion healthcare spending and 34.4 million population. Mr. Lokman Izam Abd Aziz (Lokman), Vice President of Marketing & Communications emphasized Malaysia’s medical tourism potential, noting a 101% revenue increase since 2019 and a $10,000 health screening costing under $800. Ms. Nisha Tamzamrat (Nisha), Source of Asia (SOA), showcased the World Health Expo Kuala Lumpur, expecting 450 exhibitors and 13,000 attendees in 2027. Ms. Rathanesh Ramasundram (Rathanesh), Head of Healthcare & Life Sciences, Frost & Sullivan, identified key investment themes: preventive healthcare, chronic disease management, elderly care, digital health, diagnostics, and medical tourism, predicting a 15% annual growth in healthcare travelers. Abdul Halim highlighted Malaysia’s unique position in the ASEAN healthcare market, emphasizing its comprehensive healthcare ecosystem, including manufacturing and clinical research. He noted Malaysia’s high healthcare expenditure per capita, which supports investment in new technologies and treatments. Lokman discussed Malaysia’s attractiveness for healthcare business and medical travelers, citing its unique selling propositions and investment opportunities across various healthcare sectors. He also mentioned the role of Malaysia Healthcare Travel Council (MHTC) in facilitating processes for international patients and investors. The session concluded with a call for further engagement and partnerships within the ASEAN healthcare market. Outline Abdul Halim Mohamed Shariff’s Presentation on Malaysia as a Strategic Investment Platform Abdul Halim introduces MATRADE and its role in promoting Malaysian companies internationally. Abdul Halim discusses the growth of the global healthcare industry, predicting a $11.3 trillion market by 2030. He highlights the challenges faced by the global healthcare industry, including lifestyle changes, aging population, and technological gaps. Abdul Halim emphasizes Malaysia’s strategic location and advantages, such as political stability and connectivity, making it a hub for the healthcare industry. Abdul Halim explains Malaysia’s two-tier healthcare system: public and private, with the private sector driven by insurance and healthcare tourism. He highlights the growth of private hospitals and the increasing demand for healthcare services in Malaysia. Abdul Halim discusses the opportunities in the healthcare industry, including preventive lifestyle services and aged care living. He mentions the government’s focus on developing the healthcare product-related manufacturing and reforming the healthcare services. Lokman Izam Abd Aziz’s Presentation on Medical Tourism Excellence in Malaysia Lokman introduces the Malaysia Healthcare Travel Council (MHTC) and its role in positioning Malaysia as a leading healthcare travel destination. Lokman explains the patient journey in medical tourism and the importance of trust, partnerships, and capital in the industry. He highlights the global growth of the medical tourism market and Malaysia’s strong growth in the sector. Lokman discusses the multiplier effect of medical tourism on various industries and the importance of nurturing trust among patients. Nisha Tamzamrat’s Presentation on Connecting to ASEAN Healthcare Business Nisha introduces World Health Expo Kuala Lumpur (WHX Kuala Lumpur) and its role in connecting international business with opportunities across the ASEAN healthcare market. She highlights the ASEAN market’s potential, with a combined healthcare expenditure of $270 billion in 2026. Nisha discusses the advantages of Malaysia as a medical hub, including its strategic location, technology adoption, and competitive costs. She outlines the features of WHX Kuala Lumpur, including exhibitions, conferences, and business matching platforms. Rathanesh Ramasundram’s Presentation on Malaysia’s Private Healthcare Advantage Rathanesh discusses Malaysia’s position as a platform for ASEAN healthcare growth, emphasizing its strong ecosystem and underlying economics. He highlights the demographic changes in Malaysia, with the country expected to reach aged nation status by 2030. Rathanesh explains the opportunities in the private healthcare sector, including preventive healthcare, chronic disease management, and elderly care. He emphasizes the importance of investing in asset-light, recurring revenue models and moving beyond traditional hospital beds. Malaysia’s Unique Healthcare Ecosystem Abdul Halim Mohamed Shariff highlights that while Malaysia has a smaller population compared to Indonesia and the Philippines, it offers a unique proposition in the healthcare ecosystem. Malaysia is established in healthcare services, manufacturing, and clinical research, with the latter led by Clinical Research Malaysia. The country’s demographic profile attracts a significant number of clinical studies, enhancing its research capabilities. Abdul Halim notes that Malaysia’s high healthcare expenditure per capita, though lower than Singapore and Brunei, indicates affordability for good healthcare services and new technologies. Malaysia’s high healthcare expenditure supports the investment in new technologies and treatments, making it an attractive destination for healthcare investments. Healthcare Expenditure and Investment Opportunities Abdul Halim emphasizes that Malaysia’s high healthcare expenditure per capita complements the surrounding region, providing support through its healthcare services. The ecosystem in Malaysia extends healthcare services to the region, supporting health tourism and the overall healthcare needs of the ASEAN region. Mariyah invites Lokman Izam Abd Aziz to share his thoughts on what makes Malaysia an attractive destination for healthcare business and medical travelers. Lokman Izam Abd Aziz approaches the question from two perspectives: the unique selling propositions of Malaysia and the investment opportunities for investors. He highlights the importance of the overall ecosystem, from pre-patient care to post-patient care, and the role of MHC in easing
Celebrating Success at APHM 2026
APHM International Healthcare Exhibition 2026 (APHM 2026) marked the 32nd edition of Malaysia’s premier private healthcare event, held from July 28–30, 2026 at the Kuala Lumpur Convention Centre. With the theme “From Volume to Value: Measuring What Matters in Healthcare Performance,” the conference brought together hospital leaders, regulators, insurers, and technology innovators to explore healthcare transformation, patient safety, sustainability, and medicolegal issues. Beyond the insightful presentations by distinguished speakers, APHM 2026 showcased the strength of the healthcare industry with more than 150 exhibitors from Malaysia, ASEAN, and across the globe. This made it one of the largest healthcare trade shows in the region, featuring innovations in hospital equipment, digital health solutions, sustainability initiatives, and patient safety technologies. Global Rep was honoured to be part of this distinguished event, engaging with trusted partners and companies that continue to place their confidence in us. The exhibition also provided a valuable opportunity to meet customers face-to-face, share updates on medical device registration in Malaysia, and provide timely answers that help accelerate ongoing projects. A highlight of our participation was an in-person meeting with our potential partner from China, the Technical Consultancy Center (TCC). Renowned for their expertise in medical device regulatory registration and global market access, TCC brings deep knowledge to the table. Our discussion was open, sincere, and forwardlooking — focusing on collaboration preferences and strategic plans within ASEAN. We are excited to build on this strong foundation and move toward impactful collaborations in the near future. Global Rep is committed to continuously enhancing its services, strengthening its position in the market, and delivering valuable solutions that empower customers across the region. We warmly invite you to connect with us — let’s grow bigger, stronger, and achieve success together. Ready to Bring Your Medical Device to Malaysia and ASEAN? Partner with Global Rep for expert medical device regulatory affairs, medical device registration and faster market access. Our experienced team will guide you through every stage of the regulatory process. Let’s turn your expansion plans into progress.
ISO 13485 Certification: Your Gateway to Medical Device Market Access
ISO 13485 is the internationally recognized quality management system (QMS) standard for medical devices. It is a structured framework of policies, processes, and responsibilities that ensures an organization consistently delivers products or services that meet customer and regulatory requirements. It is widely used in Malaysia and globally to demonstrate system compliance, streamline processes, and gain market access through regulatory compliance. In Malaysia, medical device manufacturers intending to market their products must first obtain ISO 13485 certification from a Conformity Assessment Body (CAB) recognized by the Medical Device Authority (MDA). This certification serves as a mandatory prerequisite for securing the manufacturer’s license issued by the MDA and is subsequently required for product registration with the Authority. Manufacturers of Class A and Class B medical devices may exclude the design and development process from their Quality Management System (QMS). Conversely, manufacturers of Class C and Class D devices are required to incorporate the design and development process within their QMS. In all cases, manufacturers may declare the inapplicability of specific requirements, provided that such exclusions are duly justified. 15 High-Frequency Keywords in ISO 13485:2016 The following analysis provides a bird’s‑eye view of the ISO 13485 standard and highlights its key aspects. It focuses on the high‑frequency keywords found across Clauses 4, 5, 6, 7, and 8, which illustrate the primary emphasis of the standard. List Keywords Frequency Primary Clauses Focus Areas 1 Requirements 127 4, 7 Compliance obligations 2 Records 73 4, 5, 6, 7, 8 Compliance evidence 3 Quality 72 4, 5, 6, 7, 8 Central theme of QMS 4 Process 69 7, 8 Operational consistency 5 Action 54 4, 5, 6, 7, 8 Implementation 6 Regulatory 43 4, 5, 7, 8 Compliance obligations 7 Plan 41 4, 5, 7, 8 Principle of planned quality management 8 Design and Development 38 7.3 Mandatory for Class C & D devices 9 Validation 33 4, 7 Process & software validation 10 Documented 24 4, 5, 7, 8 System requirements 11 Customer 23 7, 8 Requirements, communication, feedback, complaints 12 Nonconform 21 8 Handling, correction, corrective action 13 Risk 14 4, 7 Risk management in process, design & production 14 Improvement 12 8 CAPA, continual improvement 15 Top Management 11 5 Leadership responsibility List Keywords Frequency Primary Clauses Focus Areas 1 Requirements 127 4, 7 Compliance obligations 2 Records 73 4, 5, 6, 7, 8 Compliance evidence 3 Quality 72 4, 5, 6, 7, 8 Central theme of QMS 4 Process 69 7, 8 Operational consistency 5 Action 54 4, 5, 6, 7, 8 Implementation 6 Regulatory 43 4, 5, 7, 8 Compliance obligations 7 Plan 41 4, 5, 7, 8 Principle of planned quality management 8 Design and Development 38 7.3 Mandatory for Class C & D devices 9 Validation 33 4, 7 Process & software validation 10 Documented 24 4, 5, 7, 8 System requirements 11 Customer 23 7, 8 Requirements, communication, feedback, complaints 12 Nonconform 21 8 Handling, correction, corrective action 13 Risk 14 4, 7 Risk management in process, design & production 14 Improvement 12 8 CAPA, continual improvement 15 Top Management 11 5 Leadership responsibility For more insight about ISO 13485 QMS requirements and certification process, please refer to our blog on the Foundations of Medical Device Compliance for the ISO 13485 QMS certification. Still Unsure How To Get Your Company Certified? Let us guide you through the process. You can rely on our experienced team to design and set up your QMS together with you, and to provide hands on guidance in implementing the established framework. We will stand by your side throughout the certification audits, ensuring full support until your certification is successfully granted.
Foundations of Medical Device Compliance
ISO 13485 and GDPMD are more than certifications—they are the foundation of quality and regulatory compliance in Malaysia’s medical device industry. Both serve as mandatory prerequisites for obtaining an Establishment License from the Medical Device Authority (MDA) under Act 737, making them essential for any organization operating in this field. ISO 13485 certification is mandated for establishments intending to act as the legal manufacturer of medical devices. Its requirements span the entire device lifecycle—from design and development to manufacturing, storage, installation and servicing—ensuring a robust QMS is in place. This system provides clear procedures, effective risk management, and strict control over design and development, enabling organizations to consistently meet both customer and regulatory expectations. Ongoing monitoring and continual improvement further strengthen the framework, allowing manufacturers to deliver safe, reliable medical devices with confidence. GDPMD certification, in contrast, governs the postproduction phase and is mandated for establishments serving as authorized representatives, importers, or distributors. It emphasizes controlled storage conditions, secure facilities, and protection against damage or contamination, while also requiring safe transportation and complete traceability from receipt to final delivery. Organizations must establish clear storage control and delivery procedures, utilize suitable transport vehicles, and monitor conditions during transit when necessary. Equally critical is the implementation of a robust post market surveillance system including complaint and recall system to ensure the distribution chain operates smoothly, safely, and in full compliance. Together, ISO 13485 and GDPMD form a comprehensive framework that safeguards quality from design through distribution, reinforcing trust in medical devices and strengthening confidence across the healthcare sector. Key differences between ISO13485 and GDPMD certification It is a common misconception that ISO13485 and GDPMD certification are the same. While they share a similar goal, each framework serves a distinct purpose and is designed for different stakeholders. The key differences between ISO13485 and GDPMD certification are outlined in the comparison table below: Aspect ISO 13485 Certification GDPMD Certification Requirements of · Quality Management System for Medical Devices · Good Distribution Practice for Medical Devices Origin · International standard · Malaysia’s regulatory requirements Prerequisite for obtaining · Establishment License – Manufacturer · Establishment License – Authorized Representative · Establishment License – Importer · Establishment License – Distributor Applicable to · Manufacturers · Authorized representatives · Importers · Distributors Scope · Complete product lifecycle · Post-manufacturing supply chain Main coverage · Risk management · Design & development · Production · Storage · Distribution · Installation & servicing · Post market surveillance · Improvement · Storage · Assembly · Distribution · Installation & Servicing · Post market surveillance · Improvement Certification authority CAB licensed by MDA CAB licensed by MDA Common certification cycle 3 years 3 years Surveillance audits Yearly Yearly Certification milestones 01 — Define certification scope Identify the required certification and determine its scope based on organizational roles and regulatory obligations. 02 — Train on requirements Provide targeted training to ensure understanding of applicable standards and compliance expectations. 03 — Develop system documentation Design and establish quality system documents that align with certification requirements. 04 — Train staff on implementation Educate personnel on how to apply and follow the established system in daily operations. 05 — Implement the system Put documented processes into practice across the organization to ensure consistency and compliance. 06 — Conduct internal audit Verify system effectiveness and identify gaps through independent internal auditing. 07 — Perform management review Leadership evaluates audit results, system performance, and opportunities for improvement. 08 — Undergo Stage 1 audit The certification body reviews documentation and readiness for the full system assessment. 09 — Undergo Stage 2 audit The certification body conducts a comprehensive evaluation of system implementation and effectiveness. 10 — Receive certification Upon successful completion, the certificate is issued, confirming compliance with the standards. Start Your ISO 13485 & GDPMD Certification Journey Today Establishing a practical and compliant ISO 13485 and GDPMD system is a complex undertaking that requires careful consideration of industry standards, business operations, resources, and regulatory expectations. Global Rep, with its proven track record, is a trusted regulatory service provider with experienced ISO 13485 consultants and GDPMD consultants who guide organizations through every stage of the certification journey. From system development and documentation preparation to compliance assessment and audit readiness, our team provides comprehensive support to help companies achieve certification successfully. With our expertise and continuous guidance, we help organizations not only obtain certification but also maintain sustainable, long-term compliance with evolving regulatory requirements. This article draws on insights provided by NR.
Malaysia – China Break New Ground in Regulatory Innovation – Strengthening Bilateral Collaboration for Safer, Faster Access
On 16 July 2025, Malaysia and China achieved a historic milestone by establishing the world’s first Malaysia–China Medical Device Regulatory Reliance Programme, designed to enhance regulatory efficiency and accelerate market access for eligible in‑vitro diagnostic (IVD) devices in both countries. This landmark initiative not only symbolizes regulatory innovation and mutual trust but also reinforces Malaysia’s leadership in advancing international cooperation for medical devices. Under Pilot Phase I, both regulatory authorities agreed to mutually recognize regulatory decisions for IVD devices, with implementation running from 30 July to 30 September 2025. Building on this success, the Ministry of Health Malaysia announced on 15 June 2026 the launch of a second initiative — the Malaysia–China Joint Evaluation Pilot Programme — which commenced on 1 July 2026 and will continue until 30 September 2026. This programme further strengthens bilateral collaboration by enabling joint regulatory assessments, reducing duplicative evaluations, and accelerating access to safe, effective, and high‑quality medical devices in both markets, while upholding rigorous safety standards. Requirement Phase 1Malaysia-China Medical Device Regulatory Reliance Programme Phase 2Malaysia-China Joint Evaluation Pilot Programme Malaysian-Made IVD Devices Chinese-Made IVD Devices Malaysian-Made IVD & GMD Devices China-Made IVD & GMD Devices Objectives Enhancing regulatory efficiency and accelerating market access for eligible IVD devices Enhance regulatory efficiency and accelerating market access through bilateral collaborative assessment, reducing duplicative evaluations Programme Period 30 Jul 2025 – 30 Sep 2025 1 Jul 2026 – 30 Sep 2026 Regulatory Pathway China’s Green Channel Malaysia’s Verification Pathway Full Conformity Assessment Special Channel Pilot Programme Facility Ownership Manufacturer must own and operate its facility in Malaysia Manufacturer must own and operate its facility in China Must be based in Malaysia (own & operate the mfg. facility) Must be based in China (own & operate the mfg. facility) Exclusions Third-party brand owners (e.g., rebranders, relabelers, assemblers) – – Device Classes Class B, C, or D approved by MDA Class II approved by Provincial MPA or Class III approved by NMPA Class B, C, or D (GMD or IVD) Class II or Class III (GMD or IVD) Prior Registration Status – Not stated The device MUST NOT have obtained registration certificates in Malaysia or China Priority – Applications involving rare diseases and innovative devices – – Application Limit 6 applications 6 applications – – Need Support Navigating the Malaysia–China Regulatory Pathway? If you are planning to market a medical device in Malaysia that has not yet been registered with China’s NMPA, we encourage you to contact Global Rep. With our extensive experience in managing full conformity assessments in Malaysia, we are well-positioned to ensure a smooth, efficient, and compliant medical device registration process tailored to your needs.